Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer (PLEASURABLE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03772353

Recruitment Status : Active, not recruiting

First Posted : December 11, 2018

Last Update Posted : March 7, 2023

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborator:

Jiangsu HengRui Medicine Co., Ltd.

Information provided by (Responsible Party):

Xichun Hu, Fudan University

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	June 10, 2023
Estimated Study Completion Date :	December 10, 2025

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Zhang J, Meng Y, Wang B, Wang L, Cao J, Tao Z, Li T, Yao W, Hu X. Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study. Front Oncol. 2022 Mar 7;12:775081. doi: 10.3389/fonc.2022.775081. eCollection 2022.

To Top